ticlopidine and Coronary Restenosis studies

Ticlopidine: An effective inhibitor of platelet aggregation commonly used in the placement of STENTS in CORONARY ARTERIES.
ticlopidine : A thienopyridine that is 4,5,6,7-tetrahydrothieno[3,2-c]pyridine in which the hydrogen attached to the nitrogen is replaced by an o-chlorobenzyl group.

Coronary Restenosis: Recurrent narrowing or constriction of a coronary artery following surgical procedures performed to alleviate a prior obstruction.

Research Excerpts

Excerpt	Relevance	Reference
" Direct comparison of the antiplatelet effects between ticagrelor and high-dose clopidogrel has not yet been reported in acute myocardial infarction (AMI) or coronary artery in-stent restenosis (ISR) patients with HTPR."	9.20	Ticagrelor overcomes high platelet reactivity in patients with acute myocardial infarction or coronary artery in-stent restenosis: a randomized controlled trial. ( Cao, A; Chen, T; Li, P; Liu, J; Liu, Y; Ma, L; Qin, Y; Wang, Z; Yang, Y; Zhao, X, 2015)
"ST-segment elevation myocardial infarction patients undergoing primary PCI in a regional STEMI network who received earlier pretreatment with a 600-mg loading dose of clopidogrel had less ischemic complications without increased bleeding or mortality."	9.14	Clopidogrel pretreatment in ST-elevation myocardial infarction patients transferred for percutaneous coronary intervention. ( Burke, MN; Duval, S; Henry, TD; Larson, DM; Lips, DL; Sharkey, SS; Solie, C; Steinhubl, S; Tschautscher, C, 2010)
"The PRODIGY trial aims to assess whether 24 months of clopidogrel therapy improves cardiovascular outcomes after coronary intervention in a broad all-comer patient population receiving a balanced mixture of stents with various anti-intimal hyperplasia potency."	9.14	Randomized comparison of 6- versus 24-month clopidogrel therapy after balancing anti-intimal hyperplasia stent potency in all-comer patients undergoing percutaneous coronary intervention Design and rationale for the PROlonging Dual-antiplatelet treatment ( Arcozzi, C; Borghesi, M; Campo, G; Cangiano, E; Cavazza, C; Colombo, F; Ferrari, F; Ferrari, R; Frangione, A; Kubbajeh, M; Marchesini, J; Minarelli, M; Monti, M; Parrinello, G; Percoco, G; Scalone, A; Tebaldi, M; Tumscitz, C; Valgimigli, M; Zuffi, A, 2010)
"Although cilostazol has reduced the extent of neointimal hyperplasia and restenosis in patients after bare-metal stent implantation, it is not known whether this effect occurs after DES implantation in diabetic patients."	9.13	Drug-eluting stenting followed by cilostazol treatment reduces late restenosis in patients with diabetes mellitus the DECLARE-DIABETES Trial (A Randomized Comparison of Triple Antiplatelet Therapy with Dual Antiplatelet Therapy After Drug-Eluting Stent Im ( Cho, YH; Choi, SW; Chun, KJ; Hong, MK; Kim, HS; Kim, JH; Kim, YH; Ko, JK; Lee, CW; Lee, JH; Lee, NH; Lee, SW; Park, DW; Park, JH; Park, SJ; Park, SW; Seong, IW; Yun, SC, 2008)
"Sirolimus-eluting stents (SESs) recently proved to be superior to bare metal stents (BMSs) in decreasing the need for repeat revascularization in patients with ST-segment elevation myocardial infarction (STEMI) at 1 year."	9.12	Comparison of three-year clinical outcome of sirolimus- and paclitaxel-eluting stents versus bare metal stents in patients with ST-segment elevation myocardial infarction (from the RESEARCH and T-SEARCH Registries). ( Daemen, J; de Jaegere, PP; García-García, HM; Kukreja, N; Serruys, PW; Sianos, G; Tanimoto, S; van de Sande, M; van Domburg, RT, 2007)
"Paclitaxel-eluting stents used with conventional antiplatelet therapy effectively inhibit restenosis and neointimal hyperplasia, with a safety profile similar to that of standard stents."	9.10	A paclitaxel-eluting stent for the prevention of coronary restenosis. ( Choi, D; Ho, DS; Hong, MK; Jang, Y; Lam, R; Lee, CW; Mintz, GS; Park, SJ; Park, SW; Raizner, AE; Shim, WH; Weissman, NJ, 2003)
" These P2Y12 inhibitors might be superior to clopidogrel for reducing ischemic events in patients with coronary artery disease (CAD)."	8.90	Impact of new oral or intravenous P2Y12 inhibitors and clopidogrel on major ischemic and bleeding events in patients with coronary artery disease: a meta-analysis of randomized trials. ( Fan, JY; Jin, C; Meng, J; Tang, XF; Yang, YJ; Yuan, JQ, 2014)
"Compared to clopidogrel and prasugrel, ticagrelor reduced neointimal formation, endothelial dysfunction, and peri-strut inflammation."	7.85	Effects of ticagrelor on neointimal hyperplasia and endothelial function, compared with clopidogrel and prasugrel, in a porcine coronary stent restenosis model. ( Chang, KS; Hong, YJ; Jeong, MH; Kim, HK; Kim, JH; Kim, MC; Kim, SS; Lim, HC; Lim, KS; Park, KH, 2017)
"The effects of dual antiplatelet therapy with aspirin and clopidogrel on the progression of native coronary artery disease after coronary artery bypass grafting are unknown."	7.80	Impact of clopidogrel plus aspirin versus aspirin alone on the progression of native coronary artery disease after bypass surgery: analysis from the Clopidogrel After Surgery for Coronary Artery DiseasE (CASCADE) randomized trial. ( Al-Atassi, T; Kulik, A; Le May, M; Ruel, M; Une, D; Voisine, P, 2014)
"The incidence of subacute stent thrombosis (SAT) within 30 days after stenting with a sirolimus-eluting stent (Cypher) for acute myocardial infarction (AMI) was retrospectively compared to that with bare-metal stents (BMS)."	7.73	Documented subacute stent thrombosis within thirty days after stenting with sirolimus-eluting stent (Cypher) for acute myocardial infarction: a Japanese single center retrospective non-randomized study. ( Enta, K; Fuda, Y; Higashitani, M; Horie, T; Imai, K; Ishikawa, T; Mochizuki, S; Mutoh, M; Nakano, Y; Okada, H; Sakamoto, H; Satoh, T; Yamaguchi, J, 2006)
"This study investigated the safety and efficacy of sirolimus-eluting stents (SESs) on early and late outcomes in patients with acute myocardial infarction."	7.73	[Promising efficacy of the sirolimus-eluting stent in patients with acute myocardial infarction]. ( Asai, T; Gochi, T; Hiramitsu, S; Hishida, H; Katoh, T; Maekawa, H; Matsushita, T; Morimoto, S; Murakami, Y; Murohara, T; Nomura, M; Okada, T; Ozaki, Y; Shimizu, T; Tani, T; Umeda, H; Watanabe, K; Yokoya, M; Yoshida, N, 2006)
"The antiplatelet effect of clopidogrel was studied prospectively in 60 consecutive patients who underwent primary angioplasty (percutaneous coronary intervention [PCI]) with stenting for acute ST-segment-elevation myocardial infarction (STEMI) to determine whether variability in response to clopidogrel affects clinical outcomes."	7.72	Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. ( Beinart, R; Bienart, R; Goldenberg, I; Guetta, V; Hod, H; Matetzky, S; Novikov, I; Pres, H; Savion, N; Shechter, M; Shenkman, B; Varon, D, 2004)
" The primary end point was major adverse cardiac events (death, MI, and ischemia-driven target vessel revascularization) at 12 months."	6.74	Comparison of the efficacy and safety of zotarolimus-, sirolimus-, and paclitaxel-eluting stents in patients with ST-elevation myocardial infarction. ( Cheong, SS; Cho, YH; Hong, MK; Hong, TJ; Jeong, MH; Kim, JJ; Kim, KS; Kim, YH; Lee, CW; Lee, JH; Lee, NH; Lee, SG; Lee, SH; Lim, DS; Park, DW; Park, SJ; Park, SW; Seong, IW; Seung, KB; Yang, JY; Yoon, J; Yun, SC, 2009)
"Rates of bleeding and thrombotic events were not significantly different according to 6- versus 24-month DAPT after PCI with new-generation DES in good aspirin responders."	5.20	6- versus 24-month dual antiplatelet therapy after implantation of drug-eluting stents in patients nonresistant to aspirin: the randomized, multicenter ITALIC trial. ( Armengaud, J; Barragan, P; Benamer, H; Berland, J; Blanchard, D; Boschat, J; Bressolette, E; Carrie, D; Cassat, C; Castellant, P; Cazaux, P; Champagnac, D; Darremont, O; Dauphin, R; Delarche, N; Druelles, P; Dupouy, P; Endresen, K; Furber, A; Gilard, M; Gommeaux, A; Hovasse, T; Jouve, B; Kermarrec, A; Kiss, RG; Le Breton, H; Levy, G; Lyuycx-Bore, A; Maillard, L; Majwal, T; Morice, MC; Noor, HA; Noryani, AAL; Ohlmann, P; Ormezzano, O; Paganelli, F; Sainsous, J; Schneeberger, M; Ungi, I; Wojcik, J, 2015)
"Clopidogrel is indicated for the treatment and prevention of peripheral vascular, cerebrovascular, and coronary artery diseases."	5.20	Assessment of the efficacy and tolerability of clopidogrel napadisilate in Korean patients with coronary stenting: a multicenter, prospective, open-label, randomized trial. ( Cho, DK; Kim, SH; Lee, HJ; Lee, HS; Lim, SW; Shin, J; Sung, JH, 2015)
" Direct comparison of the antiplatelet effects between ticagrelor and high-dose clopidogrel has not yet been reported in acute myocardial infarction (AMI) or coronary artery in-stent restenosis (ISR) patients with HTPR."	5.20	Ticagrelor overcomes high platelet reactivity in patients with acute myocardial infarction or coronary artery in-stent restenosis: a randomized controlled trial. ( Cao, A; Chen, T; Li, P; Liu, J; Liu, Y; Ma, L; Qin, Y; Wang, Z; Yang, Y; Zhao, X, 2015)
"The purpose of this pre-specified analysis of the PROlonging Dual antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY (PRODIGY) was to assess device-specific outcomes relative to different duration of dual antiplatelet therapy (DAPT) after Everolimus- (EES), Paclitaxel (PES), Zotarolimus- (ZES-S) eluting, or bare metal stents (BMS)."	5.17	Should duration of dual antiplatelet therapy depend on the type and/or potency of implanted stent? A pre-specified analysis from the PROlonging Dual antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY (PRODIGY). ( Borghesi, M; Ferrari, R; Parrinello, G; Tebaldi, M; Valgimigli, M; Vranckx, P, 2013)
"A regimen of 24 months of clopidogrel therapy in patients who had received a balanced mixture of drug-eluting or bare-metal stents was not significantly more effective than a 6-month clopidogrel regimen in reducing the composite of death due to any cause, myocardial infarction, or cerebrovascular accident."	5.16	Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial. ( Borghesi, M; Campo, G; Cangiano, E; Castriota, F; Cavazza, C; Colombo, F; Ferrari, R; Frangione, A; Fucà, G; Kubbajeh, M; Marchesini, J; Minarelli, M; Monti, M; Parrinello, G; Percoco, G; Scalone, A; Tebaldi, M; Tumscitz, C; Valgimigli, M; Vranckx, P, 2012)
"The Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) trial included 3602 patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention who were randomized to heparin plus a glycoprotein IIb/IIIa inhibitor (GPI) (n=1802) versus bivalirudin monotherapy (n=1800)."	5.15	Frequency and predictors of stent thrombosis after percutaneous coronary intervention in acute myocardial infarction. ( Brodie, BR; Caixeta, A; Cristea, E; Dangas, GD; Dudek, D; Guagliumi, G; Lansky, AJ; Mehran, R; Möeckel, M; Parise, H; Peruga, JZ; Stone, GW; Witzenbichler, B, 2011)
"This multicenter registry documents satisfactory safety and efficacy profiles, as evidenced by low rates of major adverse cardiac events and stent thrombosis up to 18 months, for the Excel biodegradable polymer-based sirolimus-eluting stent when used with 6 months of dual antiplatelet therapy in a "real-world" setting."	5.14	Safety and efficacy of biodegradable polymer-coated sirolimus-eluting stents in "real-world" practice: 18-month clinical and 9-month angiographic outcomes. ( Chen, X; Gao, R; Han, Y; Jiang, T; Jing, Q; Li, H; Li, Y; Li, Z; Liu, H; Liu, Y; Qiu, J; Shang, X; Xu, B; Yang, L; Zhang, H, 2009)
"ST-segment elevation myocardial infarction patients undergoing primary PCI in a regional STEMI network who received earlier pretreatment with a 600-mg loading dose of clopidogrel had less ischemic complications without increased bleeding or mortality."	5.14	Clopidogrel pretreatment in ST-elevation myocardial infarction patients transferred for percutaneous coronary intervention. ( Burke, MN; Duval, S; Henry, TD; Larson, DM; Lips, DL; Sharkey, SS; Solie, C; Steinhubl, S; Tschautscher, C, 2010)
"The PRODIGY trial aims to assess whether 24 months of clopidogrel therapy improves cardiovascular outcomes after coronary intervention in a broad all-comer patient population receiving a balanced mixture of stents with various anti-intimal hyperplasia potency."	5.14	Randomized comparison of 6- versus 24-month clopidogrel therapy after balancing anti-intimal hyperplasia stent potency in all-comer patients undergoing percutaneous coronary intervention Design and rationale for the PROlonging Dual-antiplatelet treatment ( Arcozzi, C; Borghesi, M; Campo, G; Cangiano, E; Cavazza, C; Colombo, F; Ferrari, F; Ferrari, R; Frangione, A; Kubbajeh, M; Marchesini, J; Minarelli, M; Monti, M; Parrinello, G; Percoco, G; Scalone, A; Tebaldi, M; Tumscitz, C; Valgimigli, M; Zuffi, A, 2010)
"The ISAR-REACT 2 trial was designed to assess the effect of abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after a 600-mg loading dose of clopidogrel."	5.13	Effect of abciximab on clinical and angiographic restenosis in patients with non-ST-segment elevation acute coronary syndromes. ( Dirschinger, J; Iijima, R; Kastrati, A; Mehilli, J; Ndrepepa, G; Pache, J; Schömig, A; Seyfarth, M, 2008)
"Although cilostazol has reduced the extent of neointimal hyperplasia and restenosis in patients after bare-metal stent implantation, it is not known whether this effect occurs after DES implantation in diabetic patients."	5.13	Drug-eluting stenting followed by cilostazol treatment reduces late restenosis in patients with diabetes mellitus the DECLARE-DIABETES Trial (A Randomized Comparison of Triple Antiplatelet Therapy with Dual Antiplatelet Therapy After Drug-Eluting Stent Im ( Cho, YH; Choi, SW; Chun, KJ; Hong, MK; Kim, HS; Kim, JH; Kim, YH; Ko, JK; Lee, CW; Lee, JH; Lee, NH; Lee, SW; Park, DW; Park, JH; Park, SJ; Park, SW; Seong, IW; Yun, SC, 2008)
"Sirolimus-eluting stents (SESs) recently proved to be superior to bare metal stents (BMSs) in decreasing the need for repeat revascularization in patients with ST-segment elevation myocardial infarction (STEMI) at 1 year."	5.12	Comparison of three-year clinical outcome of sirolimus- and paclitaxel-eluting stents versus bare metal stents in patients with ST-segment elevation myocardial infarction (from the RESEARCH and T-SEARCH Registries). ( Daemen, J; de Jaegere, PP; García-García, HM; Kukreja, N; Serruys, PW; Sianos, G; Tanimoto, S; van de Sande, M; van Domburg, RT, 2007)
"The findings of this study do not support a significant impact of abciximab on the risk of death and myocardial infarction in diabetic patients undergoing percutaneous coronary interventions after pretreatment with a 600-mg loading dose of clopidogrel at least 2 hours before the procedure."	5.11	Randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary interventions after treatment with a high loading dose of clopidogrel. ( Berger, PP; Bollwein, H; Dibra, A; Dirschinger, J; Dotzer, F; Kastrati, A; Mehilli, J; Pache, J; Schömig, A; Schühlen, H; von Beckerath, N, 2004)
"Paclitaxel-eluting stents used with conventional antiplatelet therapy effectively inhibit restenosis and neointimal hyperplasia, with a safety profile similar to that of standard stents."	5.10	A paclitaxel-eluting stent for the prevention of coronary restenosis. ( Choi, D; Ho, DS; Hong, MK; Jang, Y; Lam, R; Lee, CW; Mintz, GS; Park, SJ; Park, SW; Raizner, AE; Shim, WH; Weissman, NJ, 2003)
" These P2Y12 inhibitors might be superior to clopidogrel for reducing ischemic events in patients with coronary artery disease (CAD)."	4.90	Impact of new oral or intravenous P2Y12 inhibitors and clopidogrel on major ischemic and bleeding events in patients with coronary artery disease: a meta-analysis of randomized trials. ( Fan, JY; Jin, C; Meng, J; Tang, XF; Yang, YJ; Yuan, JQ, 2014)
" In the last few years, cilostazol, a phosphodiesterase (PDE) 3 inhibitor, has been tested in the setting of acute coronary syndromes: it exerts not only anti-platelet actions, but also pleiotropic effects, including inhibition on neointimal hyperplasia, therefore preventing both stent restenosis and thrombosis."	4.88	Cilostazol and primary-PCI: mirage or good alternative? ( Crea, F; D'Amario, D; Porto, I, 2012)
"Clopidogrel is recommended with aspirin for patients who undergo coronary artery bypass grafting (CABG) after non-ST elevation myocardial infarctions."	4.85	Evidence for using clopidogrel alone or in addition to aspirin in post coronary artery bypass surgery patients. ( Mathew, ST; Owora, A; Patel, JH; Stoner, JA; Thadani, U, 2009)
"The present review focuses on the roles of thromboxane A2 (TxA2) in arterial thrombosis, atherogenesis, vascular stent-related ischemic events and renal proteinuria."	4.85	Effect of pharmaceutical interventions targeting thromboxane receptors and thromboxane synthase in cardiovascular and renal diseases. ( Alberts, P; Bounameaux, H; Fontana, P; Mann, J; Sakariassen, KS; Sorensen, AS, 2009)
" In addition to aspirin, whose benefit has been clearly demonstrated in all forms of ischemic heart disease, clopidogrel, given before and after cardiac catheterization, also reduces the rate of thrombosis after stent placement."	4.82	[Advances in adjunctive pharmacological therapy for percutaneous coronary interventions]. ( Benito, B; Betriu, A; Masotti, M, 2005)
" In elective de novo lesions has shown remarkably clear lumens at follow-up angiography and intravascular ultrasound within the stented segments were observed with no lesion progression at the stent margins or thrombosis after a 2 month regimen of aspirin, and ticlopodine or clopidogrel."	4.81	Sirolimus-eluting stents: a review of experimental and clinical findings. ( Albiero, R; Colombo, A; Corvaja, N; Di Mario, C; Falotico, R; Stankovic, G; Takagi, T; Toutouzas, K, 2002)
"Compared to clopidogrel and prasugrel, ticagrelor reduced neointimal formation, endothelial dysfunction, and peri-strut inflammation."	3.85	Effects of ticagrelor on neointimal hyperplasia and endothelial function, compared with clopidogrel and prasugrel, in a porcine coronary stent restenosis model. ( Chang, KS; Hong, YJ; Jeong, MH; Kim, HK; Kim, JH; Kim, MC; Kim, SS; Lim, HC; Lim, KS; Park, KH, 2017)
" While, the incidence of adverse side effects tended to be lower, they were not statistically significant in patients with aspirin plus cilostazol."	3.81	Comparison of cilostazol and ticlopidine for one-month effectiveness and safety after elective coronary stenting. ( Hashiguchi, M; Kishino, S; Mochizuki, M; Nakazawa, R; Ohno, K; Shiga, T, 2004)
"The effects of dual antiplatelet therapy with aspirin and clopidogrel on the progression of native coronary artery disease after coronary artery bypass grafting are unknown."	3.80	Impact of clopidogrel plus aspirin versus aspirin alone on the progression of native coronary artery disease after bypass surgery: analysis from the Clopidogrel After Surgery for Coronary Artery DiseasE (CASCADE) randomized trial. ( Al-Atassi, T; Kulik, A; Le May, M; Ruel, M; Une, D; Voisine, P, 2014)
"The authors studied efficacy of the generic clopidogrel Еgithromb manufactured by EGIS PHARMACEUTICALS (Hungary) based on clinical data and parameters of light aggregometry in a total of 30 patients subjected to planned subcutaneous coronary intervention for stable angina pectoris."	3.79	[Assessment of clinical and antiaggregation efficacy of generic clopidogrel 'Egithromb' in roentgenosurgical practice]. ( Faĭl', IL; Loenko, VB; Smialovskiĭ, DV; Sorokina, EA, 2013)
" Long-term administration of cilostazol is more effective in reducing neointimal formation at non-overlapping segments of BESs in a porcine coronary model."	3.79	The impact of triple anti-platelet therapy for endothelialization and inflammatory response at overlapping bioabsorbable polymer coated drug-eluting stents in a porcine coronary model. ( Ahn, Y; Cho, JG; Hong, YJ; Jeong, MH; Kang, JC; Kim, JH; Kim, JM; Kim, KH; Lee, KH; Lim, KS; Park, DS; Park, HW; Park, JC; Park, KH; Sim, DS; Yoon, HJ; Yoon, NS, 2013)
"Between September 2007 and April 2010, twelve patients receiving double antithrombotic therapy (clopidogrel+acetylsalicylic acid) underwent transurethral resection of bladder cancer."	3.77	Endoscopic resection of bladder cancer in patients receiving double platelet antiaggregant therapy. ( Arena, D; Bozzini, G; Carmignani, L; Casellato, S; Lunelli, L; Picozzi, S; Stubinski, R, 2011)
"Reducing the dose of sirolimus eluting from a biocompatible HAp coated stent reduces signs of delayed vascular healing, without affecting neointimal hyperplasia."	3.75	Lowering the dose of sirolimus, released from a nonpolymeric hydroxyapatite coated coronary stent, reduces signs of delayed healing. ( Peters-Krabbendam, I; Serruys, PW; Sorop, O; van Beusekom, HM; van der Giessen, WJ, 2009)
"This study investigated the safety and efficacy of sirolimus-eluting stents (SESs) on early and late outcomes in patients with acute myocardial infarction."	3.73	[Promising efficacy of the sirolimus-eluting stent in patients with acute myocardial infarction]. ( Asai, T; Gochi, T; Hiramitsu, S; Hishida, H; Katoh, T; Maekawa, H; Matsushita, T; Morimoto, S; Murakami, Y; Murohara, T; Nomura, M; Okada, T; Ozaki, Y; Shimizu, T; Tani, T; Umeda, H; Watanabe, K; Yokoya, M; Yoshida, N, 2006)
"The incidence of subacute stent thrombosis (SAT) within 30 days after stenting with a sirolimus-eluting stent (Cypher) for acute myocardial infarction (AMI) was retrospectively compared to that with bare-metal stents (BMS)."	3.73	Documented subacute stent thrombosis within thirty days after stenting with sirolimus-eluting stent (Cypher) for acute myocardial infarction: a Japanese single center retrospective non-randomized study. ( Enta, K; Fuda, Y; Higashitani, M; Horie, T; Imai, K; Ishikawa, T; Mochizuki, S; Mutoh, M; Nakano, Y; Okada, H; Sakamoto, H; Satoh, T; Yamaguchi, J, 2006)
"Although drug-eluting stents (DES) significantly reduce restenosis, they require 3 to 6 months of thienopyridine therapy to prevent stent thrombosis."	3.73	Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry. ( Bach, RG; Cohen, DJ; Decker, C; Jones, PG; Kettelkamp, R; Khanal, S; Krumholz, HM; Messenger, JC; Peterson, ED; Rumsfeld, JS; Spertus, JA; Vance, C, 2006)
"The antiplatelet effect of clopidogrel was studied prospectively in 60 consecutive patients who underwent primary angioplasty (percutaneous coronary intervention [PCI]) with stenting for acute ST-segment-elevation myocardial infarction (STEMI) to determine whether variability in response to clopidogrel affects clinical outcomes."	3.72	Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. ( Beinart, R; Bienart, R; Goldenberg, I; Guetta, V; Hod, H; Matetzky, S; Novikov, I; Pres, H; Savion, N; Shechter, M; Shenkman, B; Varon, D, 2004)
"Our study offers preliminary evidence that patients receiving a new PCI procedure for ISR may benefit from long-term administration of aspirin plus clopidogrel."	2.79	Short- versus long-term duration of dual antiplatelet therapy in patients treated for in-stent restenosis: a PRODIGY trial substudy (Prolonging Dual Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia). ( Biscaglia, S; Campo, G; Ferrari, R; Tebaldi, M; Tumscitz, C; Valgimigli, M; Vranckx, P, 2014)
"Aspirin was to be given indefinitely, and clopidogrel/ticlopidine for ≥ 3 months or up to 12 months after implantation."	2.79	Modifying effect of dual antiplatelet therapy on incidence of stent thrombosis according to implanted drug-eluting stent type. ( Al Kurdi, M; Boersma, E; Camenzind, E; Mauri, L; Ordoubadi, FF; Rademaker-Havinga, T; Steg, PG; Suttorp, MJ; Wijns, W, 2014)
"tirofiban may allow temporary withdrawal of oral clopidogrel without increasing the risk of bleeding."	2.75	Urgent surgery in patients with a recently implanted coronary drug-eluting stent: a phase II study of 'bridging' antiplatelet therapy with tirofiban during temporary withdrawal of clopidogrel. ( Barlocco, F; Caracciolo, M; D'Urbano, M; De Servi, S; Klugmann, S; Mariani, G; Nichelatti, M; Savonitto, S, 2010)
" The primary end point was major adverse cardiac events (death, MI, and ischemia-driven target vessel revascularization) at 12 months."	2.74	Comparison of the efficacy and safety of zotarolimus-, sirolimus-, and paclitaxel-eluting stents in patients with ST-elevation myocardial infarction. ( Cheong, SS; Cho, YH; Hong, MK; Hong, TJ; Jeong, MH; Kim, JJ; Kim, KS; Kim, YH; Lee, CW; Lee, JH; Lee, NH; Lee, SG; Lee, SH; Lim, DS; Park, DW; Park, SJ; Park, SW; Seong, IW; Seung, KB; Yang, JY; Yoon, J; Yun, SC, 2009)
"0001), and major adverse cardiac events (8."	2.73	Safety of sirolimus-eluting stenting and its effect on restenosis in patients with unstable angina pectoris (a SIRIUS substudy). ( Holmes, DR; Kuntz, RE; Leon, MB; Mishkel, G; Moses, JW; Popma, JJ; Raizner, AE; Satler, LF; Teirstein, PS; Wang, P; Weisz, G; Wilensky, RL, 2007)
"Sarpogrelate treatment reduces restenosis after coronary stenting, which suggests that serotonin released from activated platelets may play an important role in stent restenosis."	2.71	Sarpogrelate treatment reduces restenosis after coronary stenting. ( Fujita, M; Ho, M; Ishii, K; Miki, O; Miwa, K; Miyamoto, A; Mizuno, K; Tsukahara, R, 2003)
"Trapidil has been shown to prevent restenosis after PTCA."	2.71	Starc II, a multicenter randomized placebo-controlled double-blind clinical trial of trapidil for 1-year clinical events and angiographic restenosis reduction after coronary angioplasty and stenting. ( Balducelli, M; Barlera, S; Bernardi, G; Latini, R; Maggioni, AP; Maresta, A; Moccetti, T; Monici Preti, A; Ribeiro da Silva, EE; Sosa, C; Varani, E, 2005)
"Cilostazol is a newly developed antiplatelet drug that has been widely applied for clinical use."	2.70	Randomized comparison of cilostazol versus ticlopidine hydrochloride for antiplatelet therapy after coronary stent implantation for prevention of late restenosis. ( Inoue, T; Kamishirado, H; Mizoguchi, K; Morooka, S; Nakata, T; Sakuma, M; Takayanagi, K; Uchida, T, 2002)
"After balloon angioplasty of a subtotal or total coronary occlusion, no reduction in adverse events was observed among patients in whom ticlopidine was added to aspirin, even after adjustment for clinical and lesion characteristics."	2.70	Does ticlopidine reduce reocclusion and other adverse events after successful balloon angioplasty of occluded coronary arteries? Results from the Total Occlusion Study of Canada (TOSCA). ( Berger, PB; Buller, CE; Catellier, D; Dzavik, V; Penn, IM, 2001)
"In this meta-analysis, TAT was associated with significantly effective outcomes for TLR and TVR without any increase in major adverse events but was associated with tolerance issues compared with DAT after DES implantation."	2.49	Cilostazol added to aspirin and clopidogrel reduces revascularization without increases in major adverse events in patients with drug-eluting stents: a meta-analysis of randomized controlled trials. ( Bonneau, HN; Kaneda, H; Koo, BK; Nagai, R; Sakurai, R, 2013)
" There is also no significant difference in major adverse cardiac and cerebrovascular events between the 2 therapies, except the smaller occurrence rate of target-lesion revascularization in the triple-therapy group (OR: 0."	2.48	The effectiveness and safety of triple-antiplatelet treatment based on cilostazol for patients receiving percutaneous coronary intervention: a meta-analysis. ( He, J; He, Y; Liu, G; Ma, C; Tang, P; Wang, P; Yang, J; Zhou, R; Zhou, S, 2012)
" If both Clopidogrel and PPI need to be prescribed, a split dosage regimen of PPI in the morning and clopidogrel in the evening can be recommended."	2.46	[Dilemma between gastroprotection and cardiovascular prevention]. ( Kandulski, A; Malfertheiner, P; Venerito, M, 2010)
" The main outcomes of the study included major adverse cardiac events (MACEs) and bleeding events during 12 months of follow-up."	1.48	The efficacy and safety of cilostazol as an alternative to aspirin in Chinese patients with aspirin intolerance after coronary stent implantation: a combined clinical study and computational system pharmacology analysis. ( Cheng, JH; Feng, ZW; Hu, ZH; Li, XY; Lv, QZ; Shi, HT; Wang, QB; Wang, Z; Wu, HY; Xie, XQ; Xu, Q; Xue, Y, 2018)
"Coronary pseudoaneurysm after bare-metal stent implantation is a rare event."	1.39	A coronary pseudoaneurysm within a restenotic stent treated by implantation of a pericardium-covered stent and drug-eluting balloon. ( Palmieri, C; Vaghetti, M, 2013)
" The effect of aspirin dosing was evaluated using χ(2) , Cochran-Mantel-Haenszel, and homogeneity testing."	1.37	Influence of low-dose aspirin (81 mg) on the incidence of definite stent thrombosis in patients receiving bare-metal and drug-eluting stents. ( Columbo, J; Cui, J; Davis, M; Giugliano, GR; Lotfi, A; Mulvey, S; Schweiger, M; Wartak, S, 2011)
"002) and major adverse cardiac events (OR: 0."	1.36	Long-term effectiveness and safety of sirolimus stent implantation for coronary in-stent restenosis results of the TRUE (Tuscany Registry of sirolimus for unselected in-stent restenosis) registry at 4 years. ( Angioli, P; Bolognese, L; Carrera, A; Ducci, K; Falsini, G; Fineschi, M; Gori, T; Grotti, S; Liistro, F; Pierli, C, 2010)
"Only amlodipine was associated with clopidogrel poor-response."	1.36	The use of amlodipine, but not of P-glycoprotein inhibiting calcium channel blockers is associated with clopidogrel poor-response. ( Breet, NJ; de Boer, A; Deneer, VH; Hackeng, CM; Harmsze, AM; Klungel, OH; Robijns, K; Ruven, HJ; Ten Berg, JM; van Werkum, JW, 2010)
"Serious allergic reactions have also been reported; (6) In most cases, especially when the risk of restenosis is low or moderate, it is better to use a bare metal stent."	1.35	Drug-eluting coronary stents: many meta-analyses, little benefit. ( , 2009)
" We assessed the cumulative incidence of major adverse cardiac events (death, acute myocardial infarction, and target-vessel revascularization) and angiographic stent thrombosis during 2-year follow-up."	1.34	Long-term safety and efficacy of drug-eluting stents: two-year results of the REAL (REgistro AngiopLastiche dell'Emilia Romagna) multicenter registry. ( Aurier, E; Benassi, A; Cremonesi, A; Grilli, R; Guastaroba, P; Magnavacchi, P; Manari, A; Maresta, A; Marzocchi, A; Percoco, G; Piovaccari, G; Saia, F; Varani, E, 2007)
"Aspirin was given starting 3 days before the intervention and administered for an additional 4 weeks."	1.33	Prevention of carotid artery restenosis after sirolimus-coated stent implantation in pigs. ( Claussen, CD; Dinkelborg, LM; Duda, SH; Laule, M; Muschick, P; Reddig, F; Tepe, G; Tielemans, H; Wehrmann, M, 2006)
" An independent endpoint review committee adjudicated all reported major adverse cardiovascular events, stent thromboses, and target-vessel revascularizations."	1.33	Safety of coronary sirolimus-eluting stents in daily clinical practice: one-year follow-up of the e-Cypher registry. ( Berge, C; Deme, M; Gershlick, AH; Guagliumi, G; Guyon, P; Lotan, C; Schofer, J; Seth, A; Sousa, JE; Stoll, HP; Urban, P; Wijns, W, 2006)
"Ticlopidine (200 mg/day) was prescribed for at least 12 weeks after SES implantation and for 2 weeks after BMS in addition to aspirin (81-100 mg/day)."	1.33	Effectiveness of a sirolimus-eluting stent (Cypher) for diffuse in-stent restenosis inside a bare metal stent. ( Fuda, Y; Higashitani, M; Horie, T; Imai, K; Ishikawa, T; Mochizuki, S; Mutoh, M; Nakano, Y; Ohta, M; Okada, H; Sakamoto, H; Tsurusaki, T, 2006)
" An adequate dosage of ticlopidine (250 mg twice daily) and aspirin (100 mg/day) led to a lower rate of stent thrombosis (6 of 2,189 cases) than inadequate dosages or missing therapy (12 of 343 cases)."	1.32	Influence of residual stenosis after percutaneous coronary intervention with stent implantation on development of restenosis and stent thrombosis. ( Hambrecht, R; Hentschel, B; Hüttl, T; Lauer, B; Niebauer, J; Schuler, G; Sick, P; Thiele, H, 2003)

Research

Studies (272)

Authors

Clinical Trials (69)

Trial Overview

Trial Outcomes

To Compare Overall Definite or Probable Stent Thrombosis Rate of the Endeavor® Zotarolimus Eluting Coronary Stent System Versus the Cypher® Sirolimus-eluting Coronary Stent in a Patient Population Requiring Stent Implantation

Composites of (Cardiac) Death and (Large) Non-fatal Myocardial Infarctions

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	173 (63.60)	29.6817
2010's	98 (36.03)	24.3611
2020's	1 (0.37)	2.80

Authors	Studies
Osama, S	1
Wirth, F	1
Zahra, G	1
Barbara, C	1
Xuereb, RG	1
Camilleri, L	1
Azzopardi, LM	1
Capodanno, D	2
Kim, HK	2
Jeong, MH	5
Lim, KS	2
Kim, JH	6
Lim, HC	1
Kim, MC	1
Hong, YJ	3
Kim, SS	1
Park, KH	3
Chang, KS	1
Piccolo, R	2
Feres, F	5
Abizaid, A	7
Gilard, M	3
Morice, MC	3
Hong, MK	9
Kim, HS	6
Colombo, A	8
Bhatt, DL	5
Palmerini, T	1
Stone, GW	3
Windecker, S	3
Valgimigli, M	8
Xue, Y	1
Feng, ZW	1
Li, XY	1
Hu, ZH	1
Xu, Q	1
Wang, Z	2
Cheng, JH	1
Shi, HT	1
Wang, QB	1
Wu, HY	1
Xie, XQ	1
Lv, QZ	1
Núñez-Gil, IJ	1
Aldazábal, A	1
Cerrato, E	1
Salinas, P	1
Pérez-Vizcayno, MJ	3
Fernández-Ortiz, A	1
Zhao, X	2
Wu, H	1
Xu, H	1
Shen, L	1
Fan, B	1
Ge, J	1
Kan, J	1
Chen, F	1
Liu, LY	1
Xu, HM	1
Lin, L	1
Liu, Y	3
Zhao, YY	1
Cheng, JP	1
Chen, SL	1
Loenko, VB	1
Sorokina, EA	1
Faĭl', IL	1
Smialovskiĭ, DV	1
Vaghetti, M	1
Palmieri, C	1
Phankingthongkum, R	1
Panchavinnin, P	1
Chinthammitr, Y	1
Tresukosol, D	1
Chotinaiwattarakul, C	1
Tungsubutra, W	1
Wongpraparut, N	1
Kitrattana, B	1
Leewanun, P	1
Lee, SW	10
Lee, JY	3
Ahn, JM	1
Park, DW	6
Han, S	1
Park, YK	1
Lee, WS	1
Jang, JY	1
Kwon, CH	1
Park, GM	1
Cho, YR	1
Kim, WJ	3
Kang, SJ	3
Kim, YH	8
Lee, CW	9
Kim, JJ	5
Park, SW	9
Park, SJ	9
Musumeci, G	1
Limbruno, U	2
Campo, G	5
Tebaldi, M	6
Vranckx, P	5
Biscaglia, S	1
Tumscitz, C	4
Ferrari, R	4
Borghesi, M	4
Cangiano, E	3
Minarelli, M	3
Scalone, A	3
Cavazza, C	3
Marchesini, J	3
Parrinello, G	4
Youn, YJ	1
Lee, JW	1
Ahn, SG	1
Lee, SH	2
Choi, H	1
Yu, CW	1
Kwon, HM	2
Jang, Y	3
Yoon, J	2
Tang, XF	1
Fan, JY	1
Meng, J	1
Jin, C	1
Yuan, JQ	1
Yang, YJ	1
Camenzind, E	1
Boersma, E	1
Wijns, W	5
Mauri, L	2
Rademaker-Havinga, T	1
Ordoubadi, FF	1
Suttorp, MJ	1
Al Kurdi, M	1
Steg, PG	2
López Mínguez, JR	1
Nogales Asensio, JM	1
Doncel Vecino, LJ	1
Sandoval, J	1
Romany, S	1
Martínez Romero, P	1
Fernández Díaz, JA	1
Fernández Portales, J	1
González Fernández, R	1
Martínez Cáceres, G	1
Merchán Herrera, A	1
Alfonso Manterola, F	1
Une, D	1
Al-Atassi, T	1
Kulik, A	1
Voisine, P	1
Le May, M	1
Ruel, M	1
Barragan, P	2
Noryani, AAL	1
Noor, HA	1
Majwal, T	1
Hovasse, T	1
Castellant, P	1
Schneeberger, M	1
Maillard, L	1
Bressolette, E	1
Wojcik, J	1
Delarche, N	1
Blanchard, D	2
Jouve, B	1
Ormezzano, O	1
Paganelli, F	2
Levy, G	1
Sainsous, J	1
Carrie, D	2
Furber, A	1
Berland, J	2
Darremont, O	1
Le Breton, H	1
Lyuycx-Bore, A	1
Gommeaux, A	1
Cassat, C	1
Kermarrec, A	1
Cazaux, P	1
Druelles, P	1
Dauphin, R	1
Armengaud, J	1
Dupouy, P	2
Champagnac, D	1
Ohlmann, P	1
Endresen, K	1
Benamer, H	2
Kiss, RG	1
Ungi, I	2
Boschat, J	1
Kim, SH	2
Sung, JH	1
Shin, J	1
Lee, HJ	1
Lee, HS	1
Cho, DK	1
Lim, SW	1
Yeh, RW	1
Kereiakes, DJ	2
Patialiakas, A	1
Thury, A	1
McFadden, E	1
Colangelo, S	1
Tondi, S	1
Roffi, M	2
Menozzi, A	1
de Cesare, N	1
Garbo, R	1
Meliga, E	1
Testa, L	1
Gabriel, HM	1
Airoldi, F	3
Ferlini, M	1
Liistro, F	2
Dellavalle, A	1
Briguori, C	1
Kandzari, DE	1
Hernandez-Perez, FJ	1
Garcia-Touchard, A	1
Restrepo-Cordoba, MA	1
Rodriguez-Gonzalez, E	1
Escudier-Villa, JM	1
Cobo-Marcos, M	1
Alonso-Pulpon, L	1
Goicolea-Ruigomez, J	1
Lee, SA	1
Suh, JW	1
Park, JJ	1
Yoon, CH	1
Cho, YS	1
Youn, TJ	1
Chae, IH	3
Choi, DJ	1
Liu, C	1
Liu, M	2
Chen, D	1
Liu, H	3
Jiang, Q	1
Lu, J	1
Zuo, L	1
Azzalini, L	1
Al-Hawwas, M	1
L'Allier, PL	1
Nozari, Y	1
Vosooghi, S	1
Boroumand, M	1
Poorhosseini, H	1
Nematipour, E	1
Salarifar, M	1
Kassaian, SE	1
Amirzadegan, A	1
Alidoosti, M	1
Haji-Zeinali, AM	1
Saroukhani, S	1
Wei, YQ	1
Wang, DG	1
Yang, H	1
Cao, H	1
Capranzano, P	2
Castiglioni, B	1
Li, P	1
Yang, Y	2
Chen, T	2
Cao, A	1
Liu, J	1
Qin, Y	1
Ma, L	1
Kagawa, Y	1
Shiode, N	1
Kawase, T	1
Tamekiyo, H	1
Okimoto, T	1
Hayashi, Y	2
Shah, RR	1
Pillai, A	1
Omar, A	1
Zhao, J	1
Arora, V	1
Kapoor, D	1
Poommipanit, P	1
Sharma, GK	1
Megaly, M	1
Ma, W	1
Liang, Y	1
Zhu, J	1
Feng, G	1
Liu, X	2
Wang, X	1
Gargiulo, G	1
Ariotti, S	1
Santucci, A	1
Baldo, A	1
Franzone, A	1
Magnani, G	1
Marino, M	1
Esposito, G	1
Cho, MH	1
Shin, DW	1
Yun, JM	1
Shin, JH	1
Lee, SP	1
Lee, H	1
Lim, YK	1
Kim, EH	1
Zuliani Mauro, MF	1
Mangione, JA	1
Costa, JR	4
Costa, R	4
Piva E Mattos, LA	1
Staico, R	4
Siqueira, D	3
Sousa, A	2
Goodman, SG	1
Nicolau, JC	1
Requena, G	1
Maguire, A	1
Blankenberg, S	1
Chen, JY	1
Granger, CB	1
Grieve, R	1
Pocock, SJ	1
Simon, T	1
Yasuda, S	1
Vega, AM	1
Brieger, D	1
Shaukat, A	1
Al-Bustami, M	1
Ong, PJ	1
Dixon, SR	2
Grines, CL	3
O'Neill, WW	2
Newsome, LT	1
Weller, RS	1
Gerancher, JC	1
Kutcher, MA	1
Royster, RL	1
Süselbeck, T	1
Haghi, D	1
Borggrefe, M	1
Kaden, JJ	1
Asano, T	1
Kobayashi, Y	1
Fukushima, K	1
Iwata, Y	1
Kitahara, H	1
Ishio, N	1
Kuroda, N	1
Komuro, I	1
Ramsdale, DR	1
Rao, A	1
Asghar, O	1
Ramsdale, KA	1
McKay, E	1
Cervinka, P	1
Bystron, M	1
Spacek, R	1
Kvasnak, M	1
Adhikari, S	1
Jakabcin, J	1
Alfonso, F	3
Hernández, R	2
Bethencourt, A	1
Martí, V	1
López-Mínguez, JR	1
Angel, J	1
Iñiguez, A	2
Morís, C	1
Cequier, A	1
Sabaté, M	2
Escaned, J	3
Jiménez-Quevedo, P	3
Bañuelos, C	3
Suárez, A	2
Macaya, C	4
Siller-Matula, JM	1
Lang, I	1
Christ, G	3
Jilma, B	1
Kleiman, NS	1
Graw, J	1
Schwenk, W	1
Volk, T	1
Amasyali, B	1
Celik, T	1
Iyisoy, A	2
Kilic, A	1
Isik, E	2
Pels, K	1
Schwimmbeck, PL	1
Rosenthal, P	2
Loddenkemper, C	1
Dang-Heine, C	1
Rauch, U	2
Martens, H	1
Schultheiss, HP	2
Dechend, R	1
Deiner, C	1
Brilakis, ES	1
Lichtenwalter, C	1
de Lemos, JA	1
Roesle, M	1
Obel, O	1
Haagen, D	1
Saeed, B	1
Gadiparthi, C	1
Bissett, JK	1
Sachdeva, R	1
Voudris, VV	1
Karyofillis, P	1
Kar, B	1
Rossen, J	1
Fasseas, P	1
Berger, P	2
Banerjee, S	1
Byrne, RA	3
Schulz, S	3
Mehilli, J	9
Iijima, R	3
Massberg, S	3
Neumann, FJ	2
ten Berg, JM	5
Schömig, A	9
Kastrati, A	9
Mirabella, F	1
Francaviglia, B	1
Di Salvo, ME	1
Galassi, AR	1
Ussia, GP	1
Tamburino, C	3
Ben-Dor, I	1
Waksman, R	7
Wozakowska-Kapłon, B	1
Młodnicki, M	1
Gutkowski, W	1
Rogacka, R	1
Chieffo, A	2
Michev, I	2
Latib, A	1
Cosgrave, J	2
Montorfano, M	1
Carlino, M	1
Sangiorgi, GM	2
Castelli, A	1
Godino, C	1
Magni, V	1
Aranzulla, TC	1
Romagnoli, E	1
Bruskina, O	1
Pache, J	3
Seyfarth, M	2
Laugwitz, KL	1
Dirschinger, J	6
Jähne, J	2
Schirren, J	2
Rottbauer, W	1
Katus, HA	1
Bölükbas, S	1
Martens, A	1
Haverich, A	1
Tanajura, LF	2
Mattos, LA	1
Sousa, AG	2
Bonan, R	2
Sousa, JE	4
van der Giessen, WJ	2
Sorop, O	1
Serruys, PW	3
Peters-Krabbendam, I	1
van Beusekom, HM	1
Margolis, JR	1
Han, Y	1
Jing, Q	1
Xu, B	1
Yang, L	1
Shang, X	1
Jiang, T	1
Li, Z	1
Zhang, H	1
Li, H	1
Qiu, J	1
Li, Y	1
Chen, X	1
Gao, R	1
Maldonado, G	1
Doi, H	1
Maehara, A	1
Mintz, GS	4
Costa, Jde R	1
Sano, K	1
Weisz, G	3
Dangas, GD	2
Lansky, AJ	4
Kreps, EM	1
Collins, M	1
Fahy, M	1
Moses, JW	7
Leon, MB	7
Mehran, R	3

Trial	Phase	Enrollment	Study Type	Start Date	Status
PROlonging Dual Antiplatelet Treatment In Patients With Coronary Artery Disease After Graded Stent-induced Intimal Hyperplasia studY[NCT00611286]	Phase 4	1,700 participants (Anticipated)	Interventional	2006-12-31	Completed
Short-term Outcomes of Elective High-risk PCI With Extracorporeal Membrane Oxygenation Support: a Single-centre Registry[NCT05387902]		25 participants (Actual)	Observational [Patient Registry]	2022-02-03	Completed
A Trial of Evaluating Additional Benefit of Cilostazol to Dual Antiplatelet Therapy in Patients With Long or Multi-vessel Coronary Artery Disease Underwent Biolimus-Eluting Stent Implantation[NCT01192724]	Phase 4	630 participants (Actual)	Interventional	2010-03-31	Completed
PROTECT Trial: Patient Related OuTcomes With Endeavor Versus Cypher Stenting Trial[NCT00476957]	Phase 4	8,709 participants (Actual)	Interventional	2007-06-30	Completed
Impact of Preoperative FFR on Arterial Bypass Graft Functionality: Towards a New CABG Paradigm[NCT02527044]		120 participants (Anticipated)	Interventional	2015-11-30	Active, not recruiting
Clopidogrel After Surgery for Coronary Artery Disease (CASCADE Trial): Does Clopidogrel Prevent Saphenous Vein Graft Disease After Coronary Bypass?[NCT00228423]	Phase 2	113 participants (Actual)	Interventional	2006-05-31	Completed
Is There A LIfe for DES After Discontinuation of Clopidogrel:The ITALIC PLUS Trial[NCT01476020]		1,240 participants (Anticipated)	Observational	2011-11-30	Not yet recruiting
Zotarolimus-eluting Endeavor Sprint Stent in Uncertain DES Candidates (ZEUS) Study[NCT01385319]	Phase 3	1,606 participants (Actual)	Interventional	2011-06-30	Active, not recruiting
A Multicenter Randomized Trial Evaluating the Efficacy of Sarpogrelate on Ischemic Heart Disease After Drug-eluting Stent Implantation in Patients With Diabetes Mellitus or Renal Impairment[NCT02294643]	Phase 3	220 participants (Actual)	Interventional	2009-04-30	Completed
TIGRIS: Long-Term rIsk, Clinical manaGement and Healthcare Resource Utilization of Stable Coronary Artery dISease in Post Myocardial Infarction Patients[NCT01866904]		9,284 participants (Actual)	Observational	2013-06-19	Terminated (stopped due to Study was terminated in order to secure the data quality of the study in terms of follow-up rates and data completeness.)
Prospective Study of Bioresorbable Vascular Scaffold Treatment With Scoring Balloon Pre-dilatation in Patients With In-stent Restenosis[NCT03069066]	Phase 4	100 participants (Anticipated)	Interventional	2016-01-31	Recruiting
RIBS V (Restenosis Intra-stent of Bare Metal Stents: Paclitaxel-eluting Balloon vs Everolimus-eluting Stent). A Prospective, Multicenter and Randomized Clinical Trial[NCT01239953]	Phase 4	190 participants (Actual)	Interventional	2010-01-31	Active, not recruiting
RIBS IV (Restenosis Intra-stent of Drug-eluting Stents: Paclitaxel-eluting Balloon vs Everolimus-eluting Stent). A Prospective, Multicenter and Randomized Clinical Trial[NCT01239940]	Phase 4	310 participants (Anticipated)	Interventional	2010-01-31	Recruiting
Prospective Study of Bioresorbable Vascular Scaffold Treatment in Patients With In-stent Restenosis[NCT02672878]	Phase 4	130 participants (Anticipated)	Interventional	2014-04-30	Not yet recruiting
Observational Study of Treatment of Bioresorbable Vascular Scaffolds Restenosis[NCT03167424]		100 participants (Anticipated)	Observational [Patient Registry]	2016-05-31	Recruiting
Platelet Function in Resuscitated Patients[NCT02914795]		99 participants (Actual)	Observational	2015-06-30	Completed
The SOS (Stenting Of Saphenous Vein Grafts) Randomized-controlled Trial of a Paclitaxel-eluting Stent vs. a Bare Metal Stent in Saphenous Vein Graft Lesions[NCT00247208]	Phase 3	80 participants (Actual)	Interventional	2005-05-31	Completed
Prospective, Randomized Trial of the Sirolimus-Eluting Stent and Paclitaxel-Eluting Stent for the Treatment of Unprotected Left Main Coronary Artery Disease(ISAR-LEFT-MAIN)[NCT00133237]	Phase 4	607 participants (Actual)	Interventional	2005-07-31	Completed
Multi-Center Registry Trial of EXCEL Biodegradable Polymer Drug-Eluting Stent[NCT00331578]	Phase 4	2,077 participants (Actual)	Interventional	2006-06-30	Completed
Regular DES Versus BiOSS Expert® Stent in Coronary Bifurcation Treatment - Randomized, Multicenter, Open-label, Controlled POLBOS I (POLish Bifurcation Optimal Stenting) Study[NCT02192840]	Phase 4	243 participants (Actual)	Interventional	2010-10-31	Completed
Management of Antiplatelet Regimen During Surgical Procedures (MARS Registry)[NCT03981835]		1,492 participants (Anticipated)	Observational [Patient Registry]	2019-08-01	Recruiting
A Prospective Single Arm Clinical Trial Evaluating the MitraClip System in Australia and New Zealand[NCT01301625]		78 participants (Actual)	Observational	2011-11-30	Terminated (stopped due to As recruitment rate was lower than anticipated)
Pharmacogenetics of Clopidogrel in Acute Coronary Syndromes[NCT03347435]		889 participants (Actual)	Interventional	2013-06-30	Terminated (stopped due to Ethics Committe decision)
Comparison of Triple Versus Dual Antiplatelet Therapy After ABT578-Eluting Stent Implantation For Long Coronary Lesions[NCT00589927]	Phase 4	486 participants (Anticipated)	Interventional	2007-12-31	Completed
Dual Arm Factorial Randomized Trial in Patients w/ST Segment Elevation AMI to Compare the Results of Using Anticoagulation With Either Unfractionated Heparin + Routine GP IIb/IIIa Inhibition or Bivalirudin + Bail-out GP IIb/IIIa Inhibition; and Primary An[NCT00433966]	Phase 3	3,602 participants (Actual)	Interventional	2005-03-31	Completed
Do Point-of-care Platelet Function Assays Predict Clinical Outcomes in Clopidogrel Pre-treated Patients Undergoing Elective PCI. (The POPular Study)[NCT00352014]		1,000 participants (Anticipated)	Observational	2006-01-31	Completed
Comparison of the Efficacy of Everolimus-Eluting Versus Sirolimus-Eluting Stent for Coronary Lesions[NCT00698607]	Phase 4	1,466 participants (Anticipated)	Interventional	2008-06-30	Active, not recruiting
Qvanteq Bioactive Coronary Stent System First in Man (FIM) Clinical Investigation[NCT02176265]		31 participants (Actual)	Interventional	2014-09-30	Completed
Ticagrelor With Aspirin or Alone in High-Risk Patients After Coronary Intervention[NCT02270242]	Phase 4	9,006 participants (Actual)	Interventional	2015-07-31	Completed
Intra-patient Randomized Study With Polymer Free Drug Eluting Stent Versus Abluminal Biodegradable Polymer Drug Eluting Stent With Early OCT Follow up[NCT02785237]		70 participants (Actual)	Interventional	2016-06-30	Completed
LAte Stent Strut APPosition and COverage After Drug-Eluting Stent ImplantaTIOn by Optical Coherence Tomography in PatieNts With Acute Myocardial Infarction II(APPOSITION-AMI II)[NCT02770651]		69 participants (Anticipated)	Observational	2016-05-31	Enrolling by invitation
Risk Stratification for Subclinical Leaflet Thrombosis Post TAVI Using Thromboelastography[NCT03649594]		100 participants (Anticipated)	Observational	2020-10-01	Recruiting
Prospective, Randomized, Double-Blind, Placebo-Controlled Trial of the Glycoprotein IIb/IIIa Inhibition With Abciximab in Patients With ACS Undergoing Coronary Stenting After Pretreatment With a High Loading Dose of Clopidogrel (ISAR-REACT-2)[NCT00133003]	Phase 4	2,022 participants (Actual)	Interventional	2003-03-31	Completed
Prospective, Randomized, Double-Blind, Active-Controlled, Multicenter Trial of Bivalirudin and Un-fractionated Heparin in Patients Undergoing Percutaneous Coronary Interventions. ISAR-REACT-3[NCT00262054]	Phase 4	4,570 participants (Actual)	Interventional	2005-11-30	Completed
Value of Abciximab in Patients With AMI Undergoing PCI After High Dose Clopidogrel Pretreatment (BRAVE 3)[NCT00133250]	Phase 4	800 participants (Actual)	Interventional	2003-06-30	Completed
A Double-Blind, Randomized Comparison Between Two Different Clopidogrel Maintenance Doses After Percutaneous Coronary Intervention (ISAR-CHOICE-2)[NCT00140465]	Phase 4	60 participants (Actual)	Interventional	2004-10-31	Completed
Biological Efficacy of Clopidogrel 600 mg Loading Dose Followed by 75 mg Maintenance Dose After Implantation of Drug-eluting Stents in Patients With Diabetes Mellitus or Metabolic Syndrome (SPACE)[NCT00298428]		159 participants (Actual)	Interventional	2006-05-31	Completed
Non-randomized, Open-label, Historical Control, Single Group Assignment Trial of a Reduced Dose of Unfractionated Heparin in Patients Undergoing Percutaneous Coronary Interventions[NCT00735280]	Phase 4	2,505 participants (Actual)	Interventional	2008-08-31	Completed
Revascularization With Paclitaxel-coated Balloon Angioplasty Versus Drug-eluting Stenting in Acute Myocardial Infarction - a Randomized Controlled Trial.[NCT02219802]		120 participants (Anticipated)	Interventional	2014-08-31	Not yet recruiting
SEA-SIDE: Sirolimus Versus Everolimus-eluting Stent Randomized Assessment in Bifurcated Lesions and Clinical SIgnificance of Residual siDE-branch Stenosis[NCT00697372]	Phase 4	150 participants (Actual)	Interventional	2007-09-30	Completed
Prospective Randomized Study of the Paclitaxel-Coated Balloon Catheter in Bifurcated Coronary Lesions / BABILON Study (Paclitaxel-Coated Balloon in Bifurcated Lesions)[NCT01278186]	Phase 4	190 participants (Anticipated)	Interventional	2010-06-30	Active, not recruiting
Prospective, Randomized, Single-Center Evaluation of the Cypher™ Sirolimus Eluting Coronary Stent System in the Treatment of Bifurcated Coronary Lesions[NCT00288535]	Phase 4	200 participants (Anticipated)	Interventional	2005-03-31	Recruiting
Study of Lipid Core Plaque Shift at Sites of Native Coronary Artery Bifurcation[NCT00905671]	Phase 4	20 participants (Actual)	Interventional	2009-06-30	Completed
Z-SEA-SIDE: Sirolimus Versus Everolimus Versus Zotarolimus-eluting Stent Assessment in Bifurcated Lesions and Clinical SIgnificance of Residual siDE-branch Stenosis[NCT01200693]	Phase 4	80 participants (Actual)	Interventional	2008-11-30	Completed
Approaches to Chronic Occlusions With Sirolimus Stents-Cypher (ACROSS-Cypher) Total Occlusion Study of Coronary Arteries 4 Trial[NCT00378612]	Phase 3	200 participants (Actual)	Interventional	2005-06-30	Completed
WilL LOWer Dose Aspirin be More Effective Following ACS? (WILLOW-ACS)[NCT02741817]	Phase 4	20 participants (Actual)	Interventional	2016-06-26	Completed
Prospective Pilot Study- Does Mean Platelet Volume Change With Clopidogrel in Patients With Stable Angina Undergoing Percutaneous Coronary Intervention?[NCT02550301]		100 participants (Anticipated)	Observational	2015-09-30	Not yet recruiting
Chewing Clopidogrel in Addition to Regular Oral Clopidogrel Treatment to Improve Platelets Aggregation in Patient With NON ST ELEVATION MI[NCT00889044]	Phase 3	30 participants (Anticipated)	Interventional	2009-04-30	Recruiting
Phase 4 Study of Randomized Comparison Among Oral Rapamycin Plus Bare Metal Stents Versus Drug Eluting Stents in de Novo Coronary Lesions.[NCT00552669]	Phase 4	200 participants (Actual)	Interventional	2006-01-31	Completed
ABILITY Diabetes Global[NCT04236609]		3,050 participants (Actual)	Interventional	2020-06-15	Active, not recruiting
Spot Drug-Eluting vs Full Cover Stenting for Long Coronary Stenoses: a Randomized Clinical Study[NCT00738556]		179 participants (Actual)	Interventional	2003-01-31	Completed
[NCT00000614]	Phase 3	0 participants	Interventional	1998-09-30	Completed
Prospective, Single-Arm, Multi-Centre, Observational Registry to Further Validate Safety and Efficacy of the Nobori DES in Real-World Patients[NCT01261273]		18,000 participants (Actual)	Observational	2010-08-25	Completed
BIOTRONIK-Safety and Clinical PerFormance of the Drug ELuting Orsiro Stent in the Treatment of Subjects With de Novo Coronary Artery Lesions-VI[NCT02870985]	Phase 3	440 participants (Anticipated)	Interventional	2015-07-31	Recruiting
Polypill Strategy for Evidence-Based Management of Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention in an Underserved Patient Population[NCT05514938]	Phase 2	60 participants (Anticipated)	Interventional	2022-11-30	Recruiting
Maintenance Of aNtiplatElet Therapy in Patients With Coronary Stenting Undergoing Surgery[NCT03445273]		1,800 participants (Anticipated)	Observational [Patient Registry]	2018-11-21	Not yet recruiting
Personalized Patient Data and Behavioral Nudges to Improve Adherence to Chronic Cardiovascular Medications (The Nudge Study)[NCT03973931]		9,501 participants (Actual)	Interventional	2019-07-01	Active, not recruiting
Activity of Platelets After Inhibition and Cardiovascular Events: Drug Eluting Stent Implantation in Patients With Acute Coronary Syndrome: Optical Coherence Tomography Study[NCT01239654]	Phase 3	60 participants (Actual)	Interventional	2010-09-30	Completed
A Prospective Optical Coherence Tomography Study on Completeness of Strut Coverage and Vessel Wall Response at 3-6 and 9 Months Following Paclitaxel Eluting Stent Implantation in Multivessel Coronary Artery Disease[NCT00704145]	Phase 4	30 participants (Anticipated)	Interventional	2007-11-30	Completed
In-Vivo Vascular Response of Sirolimus-,Paclitaxel- and Zotarolimus-Eluting Stents in Long Lesions Requiring Overlapping. A Prospective, Randomized, Controlled Study Using Optical Coherence Tomography[NCT00693030]	Phase 4	77 participants (Anticipated)	Interventional	2006-08-31	Recruiting
The Optical Coherence Tomography Drug Eluting Stent Investigation(OCTDESI)[NCT00776204]		60 participants (Actual)	Interventional	2008-05-31	Completed
Effect of TCFA on Neointimal Coverage After EXCEL Biodegradable Polymer-coated Sirolimus-eluting Stents Implantation at 9 Months Follow-up: Evaluated by Optical Coherence Tomography and Fractional Flow Reserve[NCT02384837]		33 participants (Actual)	Observational	2014-12-31	Completed
Prospective, Randomized, Controlled Arm Study Comparing the Coverage of the Zotarolimus-eluting Stent vs Bare Metal Stent Implanted in ST- Elevation Myocardial Infarction (STEMI).[NCT00704561]		44 participants (Actual)	Interventional	2008-04-30	Completed
A Randomized Optical Coherence Tomography Study Comparing Resolute Integrity to Biomatrix Drug-eluting Stent on the Degree of Early Stent Healing and Late Lumen Loss.The OCT-ORION Study[NCT01742507]	Phase 4	60 participants (Actual)	Interventional	2012-04-30	Completed
Vessel Injury in Relation With Strut Thickness Assessed by OCT (VISTA): A Comparison of Vascular Injury Induced by a Polymer Free Sirolimus and Probucol Eluting Stent and a Biodegradable-polymer Biolimus-eluting Stent[NCT03026465]	Phase 4	50 participants (Actual)	Interventional	2017-02-16	Completed
Frequency Domain Imaging to Determine Stent Strut Coverage and Duration of Anti-Platelet Treatment After Endeavor Stent Placement[NCT01219894]		0 participants (Actual)	Observational	2010-11-30	Withdrawn (stopped due to Number of patients to meet individual IDE requirements was not obtained.)
Optical Frequency Domain Imaging (OFDI) Determined Stent Strut Coverage and Plaque Morphology After RESOLUTE Stent Placement in Non-Insulin Dependent Diabetics Presenting With Acute Coronary Syndrome (ACS)[NCT01794949]		8 participants (Actual)	Interventional	2013-09-30	Completed
Comparison of Platelet Inhibitory Effect With Adjunctive Cilostazol Versus High Maintenance-dose ClopidogrEL in Acute Myocardial Infarction Patients According to CYP2C19 Polymorphism[NCT00915733]	Phase 4	80 participants (Actual)	Interventional	2009-05-31	Completed
Multi-Center, Single-Blind, Two-Arm, Randomized, Controlled, Non Inferiority Trial of the Conor CoStar Paclitaxel-Eluting Coronary Stent System vs the TAXUS DES in Patients With De Novo Lesions of the Native Coronary Arteries[NCT00165035]	Phase 3	1,701 participants (Actual)	Interventional	2005-05-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Intervention	participants (Number)
E-ZES	61
C-SES	75

Total death and large non-fatal myocardial infarctions Total death and non-fatal myocardial infarctions Cardiac death and large non-fatal MI Cardiac death and non-fatal myocardial infarctions (NCT00476957)
Timeframe: 3 years

Incidence of Major Adverse Coronary Events Within One Year Following Surgery

Incidence of Major Bleeding Events Within One Year Following Surgery

Vein Graft Angiographic Patency

Intervention	participants (Number)
	Total death and large non-fatal myocardial infarct	Total death and non-fatal myocardial infarctions	Cardiac death and large non-fatal MI	Cardiac death and non-fatal MI	Target lesion revascularization	Stroke	Bleeding events
C-SES	255	360	174	282	156	72	184
E-ZES	225	331	157	265	249	77	201

Intervention	Participants (Count of Participants)
75mg Clopidogrel	4
Placebo	5

Intervention	Participants (Count of Participants)
75mg Clopidogrel	1
Placebo	0

Postoperative angiogram 12 months post-CABG (NCT00228423)
Timeframe: One year following surgery

Vein Graft Intimal Area

Intervention	percentage (Number)
75mg Clopidogrel	94.3
Placebo	93.2

IVUS imaging 12 months post-CABG, and the average intimal area in the proximal 40 mm of one vein graft per patient will be assessed (NCT00228423)
Timeframe: One year following surgery

Number of Participants With Cumulative Clinical Endpoint of Death and Stent Thrombosis

Platelet Inhibition Measured With Optical Aggregometry

Intervention	mm (Mean)
75mg Clopidogrel	4.1
Placebo	4.5

Intervention	Participants (Count of Participants)
Non-resuscitated Myocardial Infarction	0
Resuscitated Myocardial Infarction	3

Median (Inter-Quartile Range) Collagen AUC values on Day 3 measured with optical aggregometry The more light signal is detected, the better thrombocyte function is. (NCT02914795)
Timeframe: day 3

Device Time

Intervention	AU*min (Median)
Non-resuscitated Myocardial Infarction	109
Resuscitated Myocardial Infarction	253.8

This is one of the Device and Procedure-Related Endpoints. Device Time is defined as the time the Steerable Guide Catheter is placed in the intra-atrial septum until the time the MitraClip Delivery System (CDS) is retracted into the Steerable Guide Catheter. Device Time is shorter in duration than Procedure Time because it does not include the time required to perform transseptal access into the left atrium. (NCT01301625)
Timeframe: At day 0 (on the day of index procedure)

Fluoroscopy Duration

Intervention	Minutes (Mean)
MitraClip Implant	91.2

This is one of the Device and Procedure-Related Endpoints. Mean fluoroscopy duration during the MitraClip procedure. (NCT01301625)
Timeframe: At day 0 (on the day of index procedure)

Number of Participants With Acute Procedural Success Rate

Intervention	Minutes (Mean)
MitraClip Implant	41.2

Defined as successful MitraClip implantation with resulting MR of 2+ or less. (NCT01301625)
Timeframe: At day 0 (on the day of index procedure)

Percentage of Participants Experiencing Death (Kaplan-Meier Analysis)

Intervention	Participants (Count of Participants)
MitraClip Implant	39

"Clinical Endpoint.~Cardiac death is defined as any death in which a cardiac cause cannot be excluded. (This includes but is not limited to acute myocardial infarction, cardiac perforation/pericardial tamponade, arrhythmia or conduction abnormality,cerebrovascular accident within 30 days of the procedure or cerebrovascular accident suspected of being related to the procedure, death due to complication of the procedure, including bleeding, vascular repair, transfusion reaction, or bypass surgery.)~Non-cardiac death is defined as a death not due to cardiac causes (as defined above)." (NCT01301625)
Timeframe: 12 months

Percentage of Participants Experiencing Death (Kaplan-Meier Analysis)

Intervention	percentage of participants (Number)
MitraClip Implant	8.3

Intervention	percentage of participants (Number)
MitraClip Implant	0.0

Intervention	percentage of participants (Number)
MitraClip Implant	6.1

Percentage of Participants Experiencing Freedom From Death and Congestive Heart Failure (Kaplan-Meier Curve Analysis)

Intervention	percentage of participants (Number)
MitraClip Implant	0.0

"Death: Defined as all causes of death for the primary safety Major Adverse Event (MAE) Endpoint.~Death is further divided into 2 categories:~A. Cardiac death is defined as death due to any of the following:~Acute myocardial infarction~Cardiac perforation/pericardial tamponade~Arrhythmia or conduction abnormality~Stroke within 30 days of the procedure or stroke suspected of being related to the procedure~Death due to any complication of the procedure, including bleeding, vascular repair, transfusion reaction, or bypass surgery~Any death for which a cardiac cause cannot be excluded. B. Non-cardiac death is defined as a death not due to cardiac causes (as defined above).~Congestive Heart Failure (CHF): Defined as a documented diagnosis of CHF on the hospital admission report or discharge summary." (NCT01301625)
Timeframe: 6 months

Percentage of Participants Experiencing Freedom From Death and Congestive Heart Failure (Kaplan-Meier Curve Analysis)

Intervention	percentage of participants (Number)
MitraClip Implant	91.5

"Death: Defined as all causes of death for the primary safety Major Adverse Event (MAE) Endpoint.~Death is further divided into 2 categories:~A. Cardiac death is defined as death due to any of the following:~Acute myocardial infarction~Cardiac perforation/pericardial tamponade~Arrhythmia or conduction abnormality~Stroke within 30 days of the procedure or stroke suspected of being related to the procedure~Death due to any complication of the procedure, including bleeding, vascular repair, transfusion reaction, or bypass surgery~Any death for which a cardiac cause cannot be excluded.~B. Non-cardiac death is defined as a death not due to cardiac causes (as defined above).~Congestive Heart Failure (CHF): Defined as a documented diagnosis of CHF on the hospital admission report or discharge summary." (NCT01301625)
Timeframe: 12 months

Percentage of Participants Experiencing Freedom From Death and Congestive Heart Failure (Kaplan-Meier Curve Analysis)

Intervention	percentage of participants (Number)
MitraClip Implant	85.3

"Death: Defined as all causes of death for the primary safety Major Adverse Event (MAE) Endpoint.~Death is further divided into 2 categories:~A. Cardiac death is defined as death due to any of the following:~Acute myocardial infarction~Cardiac perforation/pericardial tamponade~Arrhythmia or conduction abnormality~Stroke within 30 days of the procedure or stroke suspected of being related to the procedure~Death due to any complication of the procedure, including bleeding, vascular repair, transfusion reaction, or bypass surgery~Any death for which a cardiac cause cannot be excluded.~B. Non-cardiac death is defined as a death not due to cardiac causes (as defined above).~Congestive Heart Failure (CHF): Defined as a documented diagnosis of CHF on the hospital admission report or discharge summary." (NCT01301625)
Timeframe: 30 days

Percentage of Participants Experiencing Freedom From Death and Congestive Heart Failure (Kaplan-Meier Curve Analysis)

Intervention	percentage of participants (Number)
MitraClip Implant	96.1

"Death: Defined as all causes of death for the primary safety Major Adverse Event (MAE) Endpoint.~Death is further divided into 2 categories:~A. Cardiac death is defined as death due to any of the following:~Acute myocardial infarction~Cardiac perforation/pericardial tamponade~Arrhythmia or conduction abnormality~Stroke within 30 days of the procedure or stroke suspected of being related to the procedure~Death due to any complication of the procedure, including bleeding, vascular repair, transfusion reaction, or bypass surgery~Any death for which a cardiac cause cannot be excluded.~B. Non-cardiac death is defined as a death not due to cardiac causes (as defined above).~Congestive Heart Failure (CHF): Defined as a documented diagnosis of CHF on the hospital admission report or discharge summary." (NCT01301625)
Timeframe: Baseline

Post-procedure Hospital Stay

Intervention	percentage of participants (Number)
MitraClip Implant	100

This is the Economic data reported to support the MitraClip System economic analysis. It is defined as the mean duration of time that patients spent in hospital following the MitraClip procedure. (NCT01301625)
Timeframe: Post index procedure within 30 days

Post-procedure Intensive Care Unit (ICU)/Critical Care Unit (CCU)/Post-anesthesia Care Unit (PACU) Duration

Intervention	Days (Mean)
MitraClip Implant	3.4

ICU and hospital stay is defined as the mean duration of time that patients spent in the ICU (Intensive Care Unit)/ CCU (Cardiac Care Unit)/ PACU (Post-Anesthesia Care Unit) following the MitraClip procedure. (NCT01301625)
Timeframe: Post index procedure within 30 days

Procedure Time

Intervention	Hours (Mean)
MitraClip Implant	62.1

This is one of the Device and Procedure-Related Endpoints. Procedure Time is defined as the time elapsed from the start of the transseptal procedure to the time the Steerable Guide Catheter is removed. (NCT01301625)
Timeframe: At day 0 (on the day of index procedure)

Six Minute Walking Distance

Intervention	Minutes (Mean)
MitraClip Implant	133.5

The six-minute walk test (6MWT) measures the distance an individual is able to walk over a total of six minutes on a hard, flat surface. It is a measure of a patient's exercise capacity. (NCT01301625)
Timeframe: 12 months

Six Minute Walking Distance

Intervention	Meters (Mean)
MitraClip Implant	329.9

Intervention	Meters (Mean)
MitraClip Implant	297.3

Intervention	Meters (Mean)
MitraClip Implant	324.3

Total Contrast Volume

Intervention	Meters (Mean)
MitraClip Implant	271.0

This is one of the Device and Procedure-Related Endpoints. (NCT01301625)
Timeframe: At day 0 (on the day of index procedure)

Change in Minnesota Living With Heart Failure (MLWHF) Quality of Life (QOL) Score From Baseline to 12 Months

Intervention	Milliliters (Mean)
MitraClip Implant	10.6

"The Minnesota Living with Heart Failure Questionnaire(MLHFQ) is comprised of 21 questions.The response for each question ranges from 0(no affect on the patient's living) to 5(affected the patient's life very much during the past month).The total score for the 21 items can range from 0-105.A lower&higher MLHFQ score indicates less effect of heart failure&the worse impact of heart failure on a patient's QOL,respectively.Although the MLHFQ incorporates relevant aspects of the key dimensions of QOL (physical and emotional),the questionnaire was not designed to measure any particular dimension separately.The total score should be taken as the best measure of how heart failure and treatments impact QOL.~The total score is the sum of a)the physical dimension,measured using 8 questions (possible subscale score range 0-40) b)the emotional dimension,measured using 5 questions(possible subscale score from 0-25)&c) other factors,measured using 8 questions (possible subscale score from 0-40)." (NCT01301625)
Timeframe: 12 months

Change in Minnesota Living With Heart Failure (MLWHF) Quality of Life (QOL) Score From Baseline to 30 Days

Intervention	scores on a scale (Mean)
	Baseline	12 months	Difference (12 months - Baseline)
MitraClip Implant	51.1	30.2	-20.9

Change in Minnesota Living With Heart Failure (MLWHF) Quality of Life (QOL) Score From Baseline to 6 Months

Intervention	scores on a scale (Mean)
	Baseline	30 days	Difference (30 days - Baseline)
MitraClip Implant	50.4	26.4	-24.0

Duration of Rehospitalization

Left Atrial Volume

Intervention	scores on a scale (Mean)
	Baseline	6 months	Difference (6 months - Baseline)
MitraClip Implant	49.5	28.0	-21.5

Intervention	Days (Mean)
	All re-hospitalizations	Heart Failure-related re-hospitalizations	Other cardiac-related re-hospitalizations	Other non-cardiac-related re-hospitalizations
MitraClip Implant	8.4	18.38	2.87	7.44

Left atrial volume is assessed by echocardiography. Using the single plane method of disks, the left atrial volume is derived by planimetry in the 4-chamber view at end-systole. (NCT01301625)
Timeframe: At Baseline and 12 Months

Left Atrial Volume

Intervention	ml (Mean)
	Baseline	12 Months
MitraClip Implant	148.5	132.4

Intervention	ml (Mean)
	Baseline	30 Days
MitraClip Implant	140.4	138.8

Left Ventricle End Diastolic Volume (LVEDV)

Intervention	ml (Mean)
	Baseline	Discharge
MitraClip Implant	141.7	141.8

Left Ventricular end-diastolic volume (LVEDV) as determined by the core echo laboratory. Left Ventricular end-diastolic volume (LVEDV) measured using 2-dimensional echocardiography. The endocardium is traced at end-diastole (frame before mitral valve closure or maximum cavity dimension) in the 2- and 4-chamber views to calculate volumes. (NCT01301625)
Timeframe: At Baseline and 12 months

Left Ventricle End Diastolic Volume (LVEDV)

Intervention	ml (Mean)
	Baseline	12 Months
MitraClip Implant	161.1	150.1

Intervention	ml (Mean)
	Baseline	30 Days
MitraClip Implant	152.9	148.2

Left Ventricular Ejection Fraction (LVEF)

Intervention	Milliliters (Mean)
	Baseline	Discharge
MitraClip Implant	158.2	151.3

Left ventricular ejection fraction is assessed by transthoracic echocardiography according to Simpson's rule (biplane method of disks). (NCT01301625)
Timeframe: At Baseline and 12 months

Left Ventricular Ejection Fraction (LVEF)

Intervention	percent (Mean)
	Baseline	12 Months
MitraClip Implant	46.9	47.4

Left ventricular ejection fraction is assessed by transthoracic echocardiography according to Simpson's rule (biplane method of disks). (NCT01301625)
Timeframe: At Baseline and 30 Days

Left Ventricular Ejection Fraction (LVEF)

Intervention	percent (Mean)
	Baseline	30 Days
MitraClip Implant	48.4	46.5

Left ventricular ejection fraction is assessed by transthoracic echocardiography according to Simpson's rule (biplane method of disks). (NCT01301625)
Timeframe: At Baseline and Discharge (≤7 days of index procedure)

Left Ventricular End Systolic Volume (LVESV)

Intervention	percent (Mean)
	Baseline	Discharge
MitraClip Implant	47.2	44.6

Left Ventricular end-systolic volume (LVESV) as determined by the core echo laboratory. Left Ventricular end-systolic volume (LVESV) measured using 2-dimensional echocardiography. The endocardium is traced at end-systole (frame prior to mitral valve opening or the minimum cavity area) in the 2- and 4-chamber views to calculate volumes. (NCT01301625)
Timeframe: At Baseline and 12 months

Left Ventricular End Systolic Volume (LVESV)

Intervention	ml (Mean)
	Baseline	12 Months
MitraClip Implant	97.8	91.7

Intervention	ml (Mean)
	Baseline	30 Days
MitraClip Implant	88.5	89.0

Left Ventricular Internal Diameter End Diastole (LVIDd)

Intervention	Milliliter (Mean)
	Baseline	Discharge
MitraClip Implant	93.3	93.2

LVIDd is the measurements of the left ventricular internal dimension at end-diastole and normally corresponds to the largest cardiac dimension. LVIDd is measured by transthoracic echocardiography and the results are interpreted by the study's echocardiography core laboratory. (NCT01301625)
Timeframe: At Baseline and 12 Months

Left Ventricular Internal Diameter End Diastole (LVIDd)

Intervention	cm (Mean)
	Baseline	12 Months
MitraClip Implant	6.0	5.7

Intervention	cm (Mean)
	Baseline	30 Days
MitraClip Implant	5.9	5.7

Left Ventricular Internal Diameter End Systole (LVIDs)

Intervention	cm (Mean)
	Baseline	Discharge
MitraClip Implant	5.9	5.7

LVIDs is the measurements of the left ventricular internal dimension at end-systole and normally corresponds to the smallest cardiac dimension. LVIDs is measured by transthoracic echocardiography and the results are interpreted by the study's echocardiography core laboratory. (NCT01301625)
Timeframe: At Baseline and 12 Months

Left Ventricular Internal Diameter End Systole (LVIDs)

Mitral Valve Area (MVA) by Pressure Half-time (PHT)

Measure of the area of the mitral valve orifice using transthoracic echocardiography. The pressure half time method is used to assess the presence and severity of mitral stenosis. Results are interpreted by the study's echocardiography core laboratory. (NCT01301625)
Timeframe: At Baseline and 12 Months

Mitral Valve Area (MVA) by Pressure Half-time (PHT)

Mitral Valve Mean Gradient

Mitral valve mean gradient is defined as the mean pressure gradients across the mitral valve as measured by echocardiography. (NCT01301625)
Timeframe: At Baseline and 12 Months

Mitral Valve Mean Gradient

Mitral valve mean gradient is defined as the mean pressure gradients across the mitral valve as measured by echocardiography. (NCT01301625)
Timeframe: At Baseline and 30 Days

Mitral Valve Mean Gradient

Mitral valve mean gradient is defined as the mean pressure gradients across the mitral valve as measured by echocardiography. (NCT01301625)
Timeframe: At Baseline and Discharge (≤7 days of index procedure)

Number of Participants at Discharge Facility

This is the economic data reported to support the MitraClip System economic analysis. (NCT01301625)
Timeframe: < or = 12 days

Number of Participants With 0, 1, 2, and 3 MitraClip Devices Implanted

This is one of the Device and Procedure-Related Endpoints. Implant Rate is defined as the rate of successful delivery and deployment of MitraClip device implant(s) with echocardiographic evidence of leaflet approximation and retrieval of the delivery catheter. (NCT01301625)
Timeframe: Day 0 (On the day of procedure)

Number of Participants With Mitral Valve Surgery

Mital Valve Surgery Post-MitraClip Procedure; Surgery Types includes Replacement and Repair. (NCT01301625)
Timeframe: 30 days of Post-MitraClip Procedure

Number of Participants With MR Severity

"Mitral regurgitation severity was determined based on the American Society of Echocardiography (ASE) Recommendations for Evaluation of The Severity of Native Valvular Regurgitation with Two-Dimensional and Doppler Echocardiography. MR severity was scored using the integrative method based on qualitative and quantitative echocardiographic parameters as described in the ASE guidelines.Site-assessed mitral regurgitation severity using echocardiography.~MR severity was graded as follows: 0: None, 1+: Mild, 2+: Moderate, 3+: Moderate-to-Severe, 4+: Severe." (NCT01301625)
Timeframe: 12 months

Number of Participants With MR Severity

Number of Participants With Second Intervention to Place an Additional MitraClip Device

Second MitraClip device interventions are reported by Abbott Vascular personnel on Procedural Observation Forms. A second MitraClip device intervention is a good option for patients with MR following placement of the original MitraClip device. (NCT01301625)
Timeframe: Through 12 months

Percentage of Participants With New York Heart Association (NYHA) Class

"Class I Patients with cardiac disease but without resulting limitations of physical activity;~Class II Patients with cardiac disease resulting in slight limitation of physical activity. Patients are comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea, or anginal pain;~Class III Patients with cardiac disease resulting in marked limitation of physical activity. They are comfortable at rest. Less than ordinary physical activity causes fatigue, palpitation dyspnea, or anginal pain;~Class IV Patients with cardiac disease resulting in inability to carry on any physical activity without discomfort. Symptoms of cardiac insufficiency or of the anginal syndrome may be present even at rest. If any physical activity is undertaken, discomfort is increased." (NCT01301625)
Timeframe: 12 months

Percentage of Participants With New York Heart Association (NYHA) Class

Rate of Patients Rehospitalized

Defined as re-admission of patients to the hospital following discharge from the Clip procedure. (NCT01301625)
Timeframe: 30 days

Regurgitant Fraction

Regurgitant fraction as determined by the core echo laboratory. Regurgitant fraction is defined as the regurgitant volume divided by the forward stroke volume through the regurgitant valve. (NCT01301625)
Timeframe: At Baseline and 12 Months

Regurgitant Fraction

Regurgitant Volume

Regurgitant volume as determined by the core echo laboratory. In the presence of regurgitation of one valve, without any intracardiac shunt, the flow through the affected valve is larger than through other competent valves. The difference between the two represents the regurgitant volume. (NCT01301625)
Timeframe: At Baseline and 12 Months

Regurgitant Volume

Pharmacology Arm - Major Adverse Cardiovascular Events

Number of participants with major adverse cardiovascular events (death, reinfarction, target-vessel revascularization for ischemia, and stroke) (NCT00433966)
Timeframe: 3 years

Pharmacology Arm - Major Adverse Cardiovascular Events

Number of participants with major adverse cardiovascular events (death, reinfarction, target-vessel revascularization for ischemia, and stroke) (NCT00433966)
Timeframe: 30 days

Pharmacology Arm - Major Adverse Ischemic Cardiac Events and Major Bleeding Events

Number of participants with major adverse cardiovascular events (death, reinfarction, target-vessel revascularization for ischemia, and stroke) and major bleeding (bleeding adjudicated as not related to coronary artery bypass grafting). (NCT00433966)
Timeframe: 30 Days

Pharmacology Arm - Non-Coronary Artery Bypass Grafting-Related Major Bleeding

Number of participants with major bleeding (bleeding adjudicated as not related to coronary artery bypass grafting) (NCT00433966)
Timeframe: 30 days

Stent Arm - Death, Reinfarction, Stroke, or Stent Thrombosis

Number of Participants With Death, Reinfarction, Stroke, or Stent Thrombosis (NCT00433966)
Timeframe: 1 year

Stent Arm - Ischemic Target Lesion Revascularization

Number of Participants With Ischemic Target Lesion Revascularization (NCT00433966)
Timeframe: 1 year

Stent Arm - Segment Binary Angiographic Restenosis

Number of Participants With Segment Binary Angiographic Restenosis (13-month Angiographic Subset). (NCT00433966)
Timeframe: 13 months

Number of Participants With BARC Type 2, 3, or 5

Number of participants with first occurrence of clinically relevant bleeding episode, defined as Bleeding Academic Research Consortium (BARC) Types 2, 3 or 5 bleeding. BARC bleeding types range from 0 (no bleeding) to 5 (fatal bleeding). (NCT02270242)
Timeframe: 12 months after randomization

Number of Participants With Ischemic Episode

Number of participants with first occurrence of confirmed all-cause death, non-fatal myocardial infarction or stroke. (NCT02270242)
Timeframe: 12 months after randomization

Differences in Costs Between Two Revascularization Strategies for de Novo Coronary Lesions.

Overall costs expressed in US dollars at 18 months of follow up between Oral Sirolimus Plus BMS vs DES implantation in denovo coronary lesions. (NCT00552669)
Timeframe: Follow up will be conducted by the coordinating Center at 18 months of follow up

Target Vessel Revascularization (TVR)

Efficacy end point was TVR as revasacularization of the treated vessel. (NCT00552669)
Timeframe: 18 months

Major Adverse Cardiovascular Events (MACCE)

Death from any cause, myocardial infarction and stroke. Safety was analyzed as MACCE (major adverse cardiovascular events) including death, MI and stroke. (NCT00552669)
Timeframe: 18 Months

Percent Stent Coverage

Assessment of vascular healing 6 months after Resolute Integrity placement in non-diabetic patients and patients with non-insulin dependent diabetes presenting with acute coronary syndrome (ACS) using optical frequency domain imaging (OFDI). Vascular healing will be measured by percent covered stents as determined by OFDI. A higher percentage of stent coverage indicates increased endothelial regrowth, which is an essential component for the maintenance of long-term luminal patency. (NCT01794949)
Timeframe: 6 months

Intervention	percentage of participants (Number)
	NYHA I	NYHA II	NYHA III	NYHA IV
MitraClip Implant	52.5	42.5	2.5	2.5

Intervention	percentage of participants (Number)
	NYHA I	NYHA II	NYHA III	NYHA IV
MitraClip Implant	36.2	44.9	15.9	2.9

Intervention	Participants (Count of Participants)
	Home	Home with home health care	Skilled nursing facility	Nursing home	Death	Other
MitraClip Implant	70	4	1	0	2	1

Intervention	Participants (Count of Participants)
	0 Mitra Clip devices	1 Mitra Clip devices	2 Mitra Clip devices	3 Mitra Clip devices
MitraClip Implant	1	41	35	1

Intervention	Participants (Count of Participants)
	Recurring mitral regurgitation	Device failure
MitraClip Implant	1	1

Intervention	Participants (Count of Participants)
	0: None	1+:Mild	2+: Moderate	3+: Moderate-to-Severe	4+: Severe	Not Evaluable
MitraClip Implant	2	15	15	7	3	0

Intervention	Participants (Count of Participants)
	Recurring mitral regurgitation	Single leaflet device attachment (SLDA)
MitraClip Implant	2	1

Intervention	Participants (Count of Participants)
Pharmacology Arm - Bivalirudin	379
Pharmacology Arm - Unfractionated Heparin	377

Intervention	Participants (Count of Participants)
Stent Arm - Paclitaxel-Eluting Stent	181
Stent Arm - Bare Metal Stent	59

Intervention	US dollars (Mean)
Oral Sirolimus + Bare Metal Stent	5483
Drug Eluting Stents	7658.2

Intervention	participants (Number)
	MACCE	Death	Acute Myocardial Infarction	Stroke
Drug Eluting Stents	15	7	9	1
Oral Sirolimus + Bare Metal Stent	9	3	6	0

Intervention	Participants (Count of Participants)
	85% up to 90% stent coverage	90% up to 95% stent coverage	95% or greater percent stent coverage
NIDDM Patients Receiving the Resolute Stent	0	1	0
Non-diabetic Patients Receiving the Resolute Stent	1	3	1

Article	Year
Risk of Early Adverse Events After Clopidogrel Discontinuation in Patients Undergoing Short-Term Dual Antiplatelet Therapy: An Individual Participant Data Analysis. JACC. Cardiovascular interventions, 2017, 08-28, Volume: 10, Issue:16 Topics: Aged; Aspirin; Clopidogrel; Coronary Restenosis; Coronary Thrombosis; Drug Administration Schedule;	2017
Impact of new oral or intravenous P2Y12 inhibitors and clopidogrel on major ischemic and bleeding events in patients with coronary artery disease: a meta-analysis of randomized trials. Atherosclerosis, 2014, Volume: 233, Issue:2 Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Administration, Oral; Clopidogrel; Coro	2014
The year in interventional cardiology. Journal of the American College of Cardiology, 2008, Jun-17, Volume: 51, Issue:24 Topics: Acute Coronary Syndrome; American Heart Association; Angioplasty, Balloon, Coronary; Clopidogrel; Co	2008
Coronary artery stents: II. Perioperative considerations and management. Anesthesia and analgesia, 2008, Volume: 107, Issue:2 Topics: Anesthesia, Conduction; Angioplasty, Balloon, Coronary; Aspirin; Blood Loss, Surgical; Clopidogrel;	2008
[Drug-eluting stents: implications for modern coronary revascularization]. Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen, 2009, Volume: 80, Issue:6 Topics: Angioplasty, Balloon, Coronary; Aspirin; Bias; Clopidogrel; Comorbidity; Coronary Artery Bypass; Cor	2009
Evidence for using clopidogrel alone or in addition to aspirin in post coronary artery bypass surgery patients. The American journal of cardiology, 2009, Jun-15, Volume: 103, Issue:12 Topics: Aspirin; Clopidogrel; Coronary Artery Bypass; Coronary Restenosis; Drug Therapy, Combination; Electr	2009
Effect of pharmaceutical interventions targeting thromboxane receptors and thromboxane synthase in cardiovascular and renal diseases. Future cardiology, 2009, Volume: 5, Issue:5 Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; Humans;	2009
The year in interventional cardiology. Journal of the American College of Cardiology, 2010, May-18, Volume: 55, Issue:20 Topics: Adenosine; Angioplasty, Balloon, Coronary; Clinical Trials as Topic; Clopidogrel; Coronary Angiograp	2010
[Dilemma between gastroprotection and cardiovascular prevention]. Deutsche medizinische Wochenschrift (1946), 2010, Volume: 135, Issue:44 Topics: Alleles; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases;	2010
Is prasugrel more effective than clopidogrel at preventing future cardiac events? JAAPA : official journal of the American Academy of Physician Assistants, 2011, Volume: 24, Issue:2 Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Restenosis; Humans; Piperazines; Platelet Aggr	2011
Personalized antiplatelet therapy: review of the latest clinical evidence. Current cardiology reports, 2011, Volume: 13, Issue:4 Topics: Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Coronary Artery Disease;	2011
Anticipating and managing bleeding complications in patients with coronary stents who are receiving dual antiplatelet treatment. BMJ (Clinical research ed.), 2011, Jul-21, Volume: 343 Topics: Blood Component Transfusion; Catheters, Indwelling; Clopidogrel; Coagulants; Coronary Artery Disease	2011
Antiplatelet therapy in the era of percutaneous coronary intervention with drug-eluting balloons. EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, 2011, Volume: 7 Suppl K Topics: Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Agents; Clopidogrel; Coated Materials, Bioco	2011
Cilostazol and primary-PCI: mirage or good alternative? Current vascular pharmacology, 2012, Volume: 10, Issue:4 Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Arrhythmias, Cardiac; Aspirin; Cilostazol;	2012
The effectiveness and safety of triple-antiplatelet treatment based on cilostazol for patients receiving percutaneous coronary intervention: a meta-analysis. Clinical cardiology, 2012, Volume: 35, Issue:10 Topics: Angioplasty, Balloon, Coronary; Aspirin; Cilostazol; Clopidogrel; Confidence Intervals; Coronary Art	2012
Cilostazol added to aspirin and clopidogrel reduces revascularization without increases in major adverse events in patients with drug-eluting stents: a meta-analysis of randomized controlled trials. International journal of cardiology, 2013, Sep-01, Volume: 167, Issue:5 Topics: Aspirin; Cardiovascular Diseases; Cilostazol; Clopidogrel; Coronary Restenosis; Drug Therapy, Combin	2013
A meta-analysis of randomized controlled trials appraising the efficacy and safety of cilostazol after coronary artery stent implantation. Cardiology, 2012, Volume: 122, Issue:3 Topics: Aspirin; Blood Vessel Prosthesis; Blood Vessel Prosthesis Implantation; Cilostazol; Clopidogrel; Com	2012
Cilostazol-based triple antiplatelet therapy compared to dual antiplatelet therapy in patients with coronary stent implantation: a meta-analysis of 5,821 patients. Cardiology, 2012, Volume: 122, Issue:3 Topics: Acute Coronary Syndrome; Aspirin; Blood Vessel Prosthesis; Blood Vessel Prosthesis Implantation; Cil	2012
Controversies in the use & implementation of drug-eluting stent technology. The Indian journal of medical research, 2012, Volume: 136, Issue:6 Topics: Absorbable Implants; Aryl Hydrocarbon Hydroxylases; Aspirin; Clopidogrel; Coated Materials, Biocompa	2012
[Antiproliferative coated stents and intracoronary brachytherapy: common traits and differences]. Zeitschrift fur Kardiologie, 2002, Volume: 91, Issue:6 Topics: Brachytherapy; Cell Division; Cilostazol; Clinical Trials as Topic; Clopidogrel; Coated Materials, B	2002
Combination antiplatelet therapy: implications for pharmacists. Pharmacotherapy, 2002, Volume: 22, Issue:10 Topics: Adult; Aspirin; Clopidogrel; Coronary Restenosis; Drug Therapy, Combination; Eptifibatide; Female; H	2002
[Endovascular brachytherapy to prevent restenosis after angioplasty]. RoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin, 2003, Volume: 175, Issue:2 Topics: Angioplasty, Balloon; Angioplasty, Balloon, Coronary; Arterial Occlusive Diseases; Aspirin; Brachyth	2003
Sirolimus-eluting stents: a review of experimental and clinical findings. Zeitschrift fur Kardiologie, 2002, Volume: 91 Suppl 3 Topics: Angina Pectoris; Angioplasty, Balloon, Coronary; Animals; Aspirin; Clopidogrel; Coronary Angiography	2002
[Anti thrombotic therapy after coronary thrombolysis]. Nihon rinsho. Japanese journal of clinical medicine, 2003, Volume: 61 Suppl 4 Topics: Anticoagulants; Aspirin; Coronary Restenosis; Drug Therapy, Combination; Fibrinolytic Agents; Hepari	2003
Percutaneous coronary intervention in diabetic patients with non-ST-segment elevation acute coronary syndromes. European heart journal, 2004, Volume: 25, Issue:3 Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Artery Bypass; Coronary Artery Disease; Corona	2004
Comparison of cilostazol and ticlopidine for one-month effectiveness and safety after elective coronary stenting. Cardiovascular drugs and therapy, 2004, Volume: 18, Issue:3 Topics: Administration, Oral; Aspirin; Cilostazol; Coronary Restenosis; Coronary Stenosis; Coronary Vessels;	2004
Relationship between activated clotting time and ischemic or hemorrhagic complications: analysis of 4 recent randomized clinical trials of percutaneous coronary intervention. Circulation, 2004, Aug-24, Volume: 110, Issue:8 Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Aspirin; Bl	2004
Antithrombotic therapy during percutaneous coronary intervention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest, 2004, Volume: 126, Issue:3 Suppl Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Clopidogrel; Contraindic	2004
[Advances in adjunctive pharmacological therapy for percutaneous coronary interventions]. Revista espanola de cardiologia, 2005, Volume: 58, Issue:6 Topics: Administration, Oral; Angioplasty, Balloon, Coronary; Anticoagulants; Cardiac Catheterization; Clopi	2005
[Triplex antithrombotic therapy after coronary-stent implantation (that is absent from recommendation)]. Orvosi hetilap, 2005, Sep-11, Volume: 146, Issue:37 Topics: Aspirin; Clopidogrel; Coronary Restenosis; Coronary Stenosis; Coronary Vessels; Coumarins; Drug Ther	2005
[PCI: state of the art]. Nihon Geka Gakkai zasshi, 2006, Volume: 107, Issue:1 Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Disease; Coronary Restenosis; Humans; Japan; P	2006
Aspirin and clopidogrel resistance: consideration and management. Journal of interventional cardiology, 2006, Volume: 19, Issue:5 Topics: Adenosine; Adenosine Monophosphate; Angioplasty, Balloon, Coronary; Aspirin; Clinical Trials as Topi	2006
Understanding and minimizing late thrombosis of drug-eluting stents. Cleveland Clinic journal of medicine, 2007, Volume: 74, Issue:2 Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Restenosis; Drug Delivery Systems; Humans; Pla	2007
[The best of interventional cardiology in 2006]. Archives des maladies du coeur et des vaisseaux, 2007, Volume: 100 Spec No 1 Topics: Angioplasty, Balloon, Coronary; Cardiology; Cardiovascular Diseases; Clinical Trials as Topic; Clopi	2007
[Stents in interventional cardiology]. Medicina (Kaunas, Lithuania), 2007, Volume: 43, Issue:3 Topics: Aged; Angioplasty, Balloon, Coronary; Anti-Bacterial Agents; Anti-Inflammatory Agents; Aspirin; Clop	2007
[Cardiology 2007]. Deutsche medizinische Wochenschrift (1946), 2007, Jun-22, Volume: 132, Issue:25-26 Topics: Angioplasty, Balloon, Coronary; Cardiopulmonary Resuscitation; Cholesterol; Clopidogrel; Coronary Ar	2007
Clopidogrel and risk for acute coronary events. Current atherosclerosis reports, 2007, Volume: 9, Issue:5 Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Coronary Restenosis; Drug Therapy, Combination; Human	2007
Mortality benefit from unrestricted access to clopidogrel: too good to be true? CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2008, Feb-12, Volume: 178, Issue:4 Topics: Angioplasty, Balloon, Coronary; Canada; Clopidogrel; Coronary Restenosis; Drug Prescriptions; Health	2008
Acute profound thrombocytopenia following angioplasty: the dilemma in the management and a review of the literature. Heart (British Cardiac Society), 2001, Volume: 86, Issue:6 Topics: Abciximab; Acute Disease; Aged; Antibodies, Monoclonal; Anticoagulants; Catheterization; Clopidogrel	2001
The WRIST series--what have we learnt? Herz, 2002, Volume: 27, Issue:1 Topics: Aged; Angioplasty, Balloon, Coronary; Brachytherapy; Clopidogrel; Cohort Studies; Coronary Restenosi	2002
[Intracoronary radiation therapy in controlled and open clinical trials with afterloading systems and "hot" balloon catheters. Analysis of 6,692 patients]. Herz, 2002, Volume: 27, Issue:1 Topics: Aged; Angioplasty, Balloon, Coronary; Beta Particles; Brachytherapy; Clinical Trials as Topic; Clopi	2002